The biological half-time of hageman factor by Veltkamp, J.J. et al.
  
 
The biological half-time of hageman factor
Citation for published version (APA):
Veltkamp, J. J., Loeliger, E. A., & Hemker, H. C. (1965). The biological half-time of hageman factor.
Thrombosis et diathesis haemorrhagica, 13(1/2), 1-7.
Document status and date:
Published: 26/03/1965
Document Version:
Other version
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Jun. 2020
(@
Sonderdruck Reprint Tirago d, part
EDITORES:  K ,  M.  BRINKEOUS,  CEAPEL HI IL ;  F .  BUCENER,  n 'REIBURG/BREISGAU;  E.  DEUTSCE,WIEN;
J. E. JOB,PES. STOCKEOLM: F. KOLIER,, BASEL; J. ROSKAM, LIDGE; J.- P. SOULIER, PAR,IS; I. S. WRIGET, NIW YON,K
VOL. XIII 15 .  I I I .1965 NO. U2
ig/rt/r),
The Biological Half-Time of Hageman Factor
From the Haematology Section of the Department of Internq,l Med,icine,
(Head,: Prof. J. Muld,er, M. D.), Uniaersity Hospi,tal, Leyd,en, The Netherland,s
J. J. Vnr,rxanp, E. A. Lonr,rcnn and I{. C. Hnmrnn
F.  K .  SCI IATTAUE R-VERLAG .  STUTTGART
Exact data concerning the biological half-time of the llageman factor (fac-
tor XII) have not yet been published. Hence, pertinent data found in a patient
with Hageman trait after transfusion of normal plasma and in a second patient
suffering from acute liver dystrophy due to phosphorus intoxication seem
worth reporting.
Case Reports
Pat'ient 1.' A 63 yoar old unmarried woman (S. v. tl. 8., Iab. nr. 821/60), suffering from poly-
cythaemia vera since 1960 (pruritus, enlarged spleen, haomoglobin 19.6 go/o, red cells 7'980'000,
haematocrit 640/o, Ietcocytres 15,800, plafolot count 0.8-1.2 million), was found during blood-
clotting tests before a bone biopsy to havo Ilageman trait. The past history givos no suggestion of
congenital haemorrhagic diathesis. In spito of platelot counts of aboui; ono million, thero was no
incroased bleeding tondency. The patient's parents aro doad. Consanguinity could not, bo dotected.
Of the patients four brothers and three sisters, none of whom displays signs of haomorrhagic dia-
thesis, fivo wgro found to have complete and the othor two to havo partial Hagoman factor defi-
cioncy (19). The results obtained by haemostatic parameters aro shown in Table 1. Up to 1963 tho
polycythaemia was treated by repeatod bleodings. Incroasing thrombocytosis, however, warranted
antimitotic therapy, which was institutod clinically. During this poriod a transfusion oxporiment
was carried ouf,. Prior oxamination rovealod no cardiovascular pathology; X-ray of tho chest
disclosed signs of localized fibrosis, probably duo to an old losion of tuborculous origin, stationary
sinco its discovery in 1950; the packed cell volumo was 40o/o, and the blood volume moasurod with
chromium-labellod orythrocytes amountod to 5.7 litres (the patient weighed 71 kg, the sploon was
roughly 4 times normal size). Pulso rato and blood pressuro wore checked throughout the experi-
ment, and 600 rrrl of normal plasma (ACD excluded, cf. MethodS) wero givon over a period of
4 hours. The pationt had no fover, either after tho transfusion or during tho following fortnight.
Pa,tient 2.' In sepf,embor 1960, a 38 year old marriod woman :was admittod 36 hours after hav-
ing attempted suicido by swallowing 500 mg yellow phosphorus (8). Results of liver function tosts
indicated rapidly progrossivo, sevore liver cell damago (Table 2). The pationt's body tomperature
oscillatod around 38" C throughout the period of observation.
In spite of tho oxtremely bad prognosis, fho patient was treatod for her sovoro hepatic damage
in the usual way. Vitamin K, was given parenterally. On the eighth day after the intake of the
poison the pationt died of cerebral haomorrhage. Autopsy revoaled, in addition to massive fatty
dogoneration of the liver, corobral, renal, mesentorial, and ondocardial haemorrhagos.
Thrombm. Diathes. haemorrh. (Stuttg.)
2Tho blood level of sevoral o{ tho coagulation factors, assessod daily, appeared to decrease
oxponentially. Half-time values aro given in Tablo 3. The activity of factor IX and factor XII
was determined in plasma samples which had been storedfot 2/2 yea,rs at -25o C.
Table 1. Results of Investigation of tho llaemostatic Mechanism in Patient 1. Platelet Count and
Thrombelastogram wero Obtained on Several Occasions. Tho Ilaematocrit Value at the Time of
Blooding time (Ivy)
Capillary resistance
(Rumpoll-Leede)
Platelet count
(X'oissly-Liidin)
Platolot Morphology
(smear)
Recalcification timo
(new fubes)
Thrombelastogram
Prothrombin time
Bilirubin
SGOT
SGPT
SLDII
Delayed
3 hours
350rrrglo
s5%
t05yo
100o/o
130o/o
l00o/o
120yo
< L Y o
Normal
Tablo 2. Results of Investigations Roflecting Livor Damag.e in Patient 2, Performed on the
Second Dav and the Sovonth Dav after Admission.
Seventh day
t2.8 rngo/o
285 U
875 U
1130 U
Tablo 3. HaIf -Times (t7/2) of Factors I, II, IX, and X Found in Patient 2 (First Column) as Com-
pared to thoso X'ound undor Normal Metabolic Conditions (Second column). Tho Increase of tho
Metabolic Docay of the X'our Coagulation Factors in the Pationt as Moasured by their Respectivo
theso fnvostigations (1963) was 40-441o.
Normal
Normal
0 .8 -1 .2 .  106
Anisocytosis
Strongly prolonged
r:  31-45 min
(moan of 5 observ.:
36 min)
k:  7-10 min
m a : 5 5 - 6 0 m m
NormaI
Prothrombin consumption
Euglobulin lysis time
X'actor I (Clauss)
Factor II
Factor V
Factor VII
X'actor VIII (7)
X'actor IX
Factor X
Factor XII
CIot retraction
0.76rngl"
136 U
228 U
340 U
Ilalf -Times Averasos 2.1 Times Normal.
Patient's t/2
(hrs.)
Normal trf
(hrir.) Ratio t% 
Normal
Patient
Factor I
X'actor II
X'actor X
Factor IX
54 (8)
2e (8)
2 1 . 6  ( 8 )
t3.2
t22 (6), (s)
72  (1 ) ,  (3 ) ,  (15)
40 (2), (3)
24 (t4)
2.26
2.48
1 . 6 0
1.82
Average:2.1
3Materials anil Methoils
Blood was collected by moans of carofully dono venepuncturo in the antocubital veins, and
handled in siliconized glassware or in plastic tubes. Normal plasma to be f,ransfused was prepared
from blood freshly drawn through plastic tubos info siliconized bottles (470 ml blood and 60 ml
ACD) from two blood-bank donors who displayed normal factor XII activity (about 100o/o of
normal).
Thrombolastographic measurements were dono in plastic cuvettes (12).
The activity of factor XII was measured in a one-stage assay systom (principle of the partial
thromboplastin time) as described oarlior for factor fX (11). The recalcification clotting times
were automatically read by the coagulomoter of Schnitger (18).
Statistical ovaluation of the results was kindly porformed by Dr. E. X'. Drion, head of the
department Betoerki,ng Waarmem,ingsui,tkomstenT. N, O., J. P. Coonstraat 22,Denllaag.
Results
The coagulation time (thrombeiastographic r-yalue) of the blood of pa-
tient 1 showed considera,ble reduction after transfusion of 600 ml fresh normal
plasma. During the first two days after transfusion, r-yalues as short as 17 min
(i. e. in the normal ra,nge) were observed. The corrective effect diminished
obse rva t i on  t ime  ( -  1 ' 63y1
Fig. 1. Biological half-timo of factor XII as calculated from activities found on successive days in a
pationf with Hageman deficiency (patient 1) and another pationt suffering from acuf,o liver-dy-
strophy (pationt 2). The first-day-values were obtained 48 hours after transfusion and on the day of
admission, respectively. X'or calculation of ihe factor XII activities in patient 2 a roforoncs curvo
was used, in which the first-day clotting time valuo arbitrarily was choson as the point ropresont-
ing 100o/o.
=
o
x
L
o(,
t k31 .5hrs .
4slowly, and could be demonstrated until the 15th day after transfusion. As
shown in Fig. 1, the biological half-times of factor XII as measured in the two
patients, appeared Lo be 52 a,nd 3lTzlor.respectively. The 95o/o confidence
intervals calculated. according to student are 32-143 hrs. and '4-41t/r L:rrs.,
respectively.
The half-time found. in patient 2 (3Iy2 hrs.) was considered to be about
half the normal value because the metabolic decay of four other coagulation
factors assessed in parallel displayed an increase of 2.1 on the average (Table 3).
Hence, the biological half-time in this patient,, under normal metabolic con-
ditions wou1d. most probably have been considerably longer (13). Correction by
the factor 2.L (a figure which cannot be statistically defined as it is obtained
from ill-defined. values) results in 66 hrs. The corresponding 95o/o confidence
interval would certainly be larger t]nun 50/2-87 fwhich is 2.1 times (24-4Irk))
due to the error introduced by the multiplicand'
Discussion
The biological half-time of factor XII may be assessed after transfusion of
normal plasma into congenitally factor Xll-deficient individuals as well as
after blocked synthesis in patients who are not primarily deficient in factor XII
(acute severe liver damage).
Transfusion experiments have been performed earlier. Ratnoff and colopy
already in 1955 (17) reported a short-lasting correction of the defect in their
first patient; they concluded that Hageman factor seems to be rapidly utilized
or destroyed. Ramot and co-workers in 1956 (16) found partial correction of
the coagulation mechanism after transfusion of 50 mI of 20 day old blood into
a Hageman-deficient individual: the whole-blood clotting time decreased from
more than60 min to 10 min within half an hour aftertransfusion; the corrective
effect,, however, had apparently disappeared.36 hours later. In 1957, Larrieu and
co-workers (10) transfused- 700ml blood into aHageman-deficient patient' The
coagulation time, normalized for 24 hours after transfusion, returned to its
original value 3 days later. The results of these two experiments suggest a
short-lasting effect of transfused Hageman factor. These authors, however, did
not estimate the biological half-time of factor XII quantitatively, as was done
by Fantl and co-workers in 1961 (a). The latter found a half-time value of 2 days
in a Hageman-d.eficient patient suffering from Ehlers-Danlos s;zndrome, who
underwent extracorporeal circulation for open-heart surgely. These authors,
however, disregarded a possible increase of the metabolic decay after surgical
treatment (13). This neglect implies that the biological half-time might be
longer than 2 d.ays.
5In the transfusion experiment described in this paper, the biological half-
time of factor XIf was found tobe 52 hrs., as calculated from values between
the third and eleventh day after transfusion of 600 ml freshly prepared, intact,
normal ACD-plasma (n'ig.1) into a factor Xll-deficient recepient. The large
95o/o confidence intervul (321A2 hrs.) is due to the widely scattered points
about the regression line (see X'ig. 1). From the amount of Hageman factor
transfused (600 ml of normal plasma displaying about 100o/o Hageman factor
activity) and from the volume into which this amount is transfused lat least
4 litres (5)1, it can be calculated that the top-level of Hageman factor activity
attained immediately after transfusion can hardly exceed 15o/o if uniform
distribution over intra- and- extravascular space is assumed. Hence, a regression
line intercepting at 15o/o (Fig.1) suggests too short a half-time.
Whether the post-transfusional half-time found in patient 1 represents the
normal biological half-time of factor XIf cannot be decided as long as we have
no exact information on (a) the disappear&nce rate of other coagulation factors
in polycythaemia vera; and (b) the state of activation of transfused Hageman
factor (a possible bias caused by gradual alteration of the state of activity of
the transfused Ilageman factor in vivo could not be excluded because the kaolin
clotting time assay method was not ready for use at the time of the experiment).
The result of our second observation (patient 2), a biological half-time of
Hageman factor of 66 hrs., suggests that the value found in the polycythaemic
patient is not far from normal.
Summary
The biological half-time of factor XII was assessed (a) after transfusion of
freshly-drawn, normal intact AOD-plasma into a patient having Hageman trait
and suffering from polycythaemia vera, and (b) with blocked synthesis in a
patient suffering from acute liver dystrophy due to phosphoric intoxication.
The results obtained suggest that the biological half-time under normal condi-
tions has a value between 50 and 70 hrs.
R6sume
La demie-vie biologique du facteur Hageman a 6t6 estim6e (a) aprds trans-
fusion de plasma normal et intact chez une malade souffrant d' < Hageman-
trait > et atteinte de polycythdmie waie, (b) aprds arr6t de la synthdse du
facteur XII chez une malade ayant une dystrophie h6patique aigud (intoxi-
cation au phosphore). Dans des conditions normales, une demie-vie de l'ordre
de 50-70 hrs. semble la plus probable.
6Zusammenfassung
Die biologische Halbwertszeit des X'aktor XII wurde bestimmt (a) nach
Transfusion von intaktem X'rischplasma bei einer Patientin mit Polycythaemia
vera und Hageman-X'aktor-Mangel, und (b)nach Stillstand der Hageman-n'ak-
tor-Synthese bei einer Patientin mit akuter Leberdystrophie (Phosphorintoxi-
kation). .frine Zeit, zwischen 50 und 70 Std. erscheint fiir den Normalwert am
wahrscheinlichsten.
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